Exciting News from ACA Pharma!

Yesterday, we celebrated a significant milestone with the issuance of the first prescription for Deflazacort (marketed as Emflaza in the U.S.), an orphan drug we registered, directly at Beijing’s prestigious Union Hospital. This event underscores our commitment to enhancing access to treatments for rare diseases throughout China.

Milestone for ACA Pharma and Patient Care in China

We are thrilled to share an important milestone for our company and patient care in China. Yesterday, our orphan drug, Diftotecan, was prescribed for the first time at Peking Union Medical College Hospital in Beijing. This event marks a significant advancement in the treatment of rare diseases in the region.

Media Coverage

The ceremony received extensive media coverage, with reports from major outlets including CCTV, Xinhua, Beijing Daily, Beijing Evening News, Health News, and Science and Technology Daily. The event was also featured prominently in last night’s CCTV news broadcast, underscoring the significance of this achievement.

Transforming Healthcare Access in China with Fast-Track Drug Registration in Macau.

Last year alone, we successfully registered over 40 new drugs from Europe and the United States. We continue to provide the fastest pathway for all pharmaceutical companies with new and orphan drugs to enter the Chinese market through our 30 to 90-day registration process in Macao. With a 100% success rate, zero investment required, and a turnaround time of 30 to 90 days, we offer unparalleled support for manufacturers.

Looking forward to continued progress in enhancing healthcare access in China